219 related articles for article (PubMed ID: 28320715)
1. Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis.
Lestner J; McEntee L; Johnson A; Livermore J; Whalley S; Schwartz J; Perfect JR; Harrison T; Hope W
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320715
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients.
O'Connor L; Livermore J; Sharp AD; Goodwin J; Gregson L; Howard SJ; Felton TW; Schwartz JA; Neely MN; Harrison TS; Perfect JR; Hope WW
J Infect Dis; 2013 Jul; 208(2):351-61. PubMed ID: 23599314
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.
Sudan A; Livermore J; Howard SJ; Al-Nakeeb Z; Sharp A; Goodwin J; Gregson L; Warn PA; Felton TW; Perfect JR; Harrison TS; Hope WW
Antimicrob Agents Chemother; 2013 Jun; 57(6):2793-800. PubMed ID: 23571544
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days.
Livermore J; Howard SJ; Sharp AD; Goodwin J; Gregson L; Felton T; Schwartz JA; Walker C; Moser B; Müller W; Harrison TS; Perfect JR; Hope WW
mBio; 2014 Jan; 5(1):e00725-13. PubMed ID: 24473125
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis.
Kovanda LL; Giamberardino C; McEntee L; Toffaletti DL; Franke KS; Bartuska A; Smilnak G; de Castro GC; Ripple K; Hope WW; Perfect JR
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31209006
[No Abstract] [Full Text] [Related]
6. In vitro-clinical correlations for amphotericin B susceptibility in AIDS-associated cryptococcal meningitis.
Larsen RA; Bauer M; Brouwer AE; Sanchez A; Thomas AM; Rajanuwong A; Chierakul W; Peacock SJ; Day N; White NJ; Rinaldi MG; Harrison TS
Antimicrob Agents Chemother; 2007 Jan; 51(1):343-5. PubMed ID: 17060519
[TBL] [Abstract][Full Text] [Related]
7. A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B.
Pitisuttithum P; Tansuphasawadikul S; Simpson AJ; Howe PA; White NJ
J Infect; 2001 Nov; 43(4):226-33. PubMed ID: 11869059
[TBL] [Abstract][Full Text] [Related]
8. Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.
Wiederhold NP; Najvar LK; Bocanegra R; Kirkpatrick WR; Sorrell TC; Patterson TF
Antimicrob Agents Chemother; 2013 Feb; 57(2):745-50. PubMed ID: 23165465
[TBL] [Abstract][Full Text] [Related]
9. Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance.
Hope W; Stone NRH; Johnson A; McEntee L; Farrington N; Santoro-Castelazo A; Liu X; Lucaci A; Hughes M; Oliver JD; Giamberardino C; Mfinanga S; Harrison TS; Perfect JR; Bicanic T
mBio; 2019 Dec; 10(6):. PubMed ID: 31796539
[TBL] [Abstract][Full Text] [Related]
10. Liposomal amphotericin B (Fungisome) for the treatment of cryptococcal meningitis in HIV/AIDS patients in India: a multicentric, randomized controlled trial.
Jadhav MP; Bamba A; Shinde VM; Gogtay N; Kshirsagar NA; Bichile LS; Mathai D; Sharma A; Varma S; Digumarathi R
J Postgrad Med; 2010; 56(2):71-5. PubMed ID: 20622383
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Oral Encochleated Amphotericin B in a Mouse Model of Cryptococcal Meningoencephalitis.
Lu R; Hollingsworth C; Qiu J; Wang A; Hughes E; Xin X; Konrath KM; Elsegeiny W; Park YD; Atakulu L; Craft JC; Tramont EC; Mannino R; Williamson PR
mBio; 2019 May; 10(3):. PubMed ID: 31138748
[No Abstract] [Full Text] [Related]
12. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.
Brouwer AE; Rajanuwong A; Chierakul W; Griffin GE; Larsen RA; White NJ; Harrison TS
Lancet; 2004 May; 363(9423):1764-7. PubMed ID: 15172774
[TBL] [Abstract][Full Text] [Related]
13. Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease.
Nixon GL; McEntee L; Johnson A; Farrington N; Whalley S; Livermore J; Natal C; Washbourn G; Bibby J; Berry N; Lestner J; Truong M; Owen A; Lalloo D; Charles I; Hope W
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29311092
[TBL] [Abstract][Full Text] [Related]
14. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.
Perfect JR; Cox GM; Dodge RK; Schell WA
Antimicrob Agents Chemother; 1996 Aug; 40(8):1910-3. PubMed ID: 8843302
[TBL] [Abstract][Full Text] [Related]
16. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis.
Larsen RA; Bauer M; Thomas AM; Graybill JR
Antimicrob Agents Chemother; 2004 Mar; 48(3):985-91. PubMed ID: 14982793
[TBL] [Abstract][Full Text] [Related]
17. Cryptococcal meningoencephalitis diagnosed by blood culture.
Sivasangeetha K; Harish BN; Sujatha S; Parija SC; Dutta TK
Indian J Med Microbiol; 2007 Jul; 25(3):282-4. PubMed ID: 17901653
[TBL] [Abstract][Full Text] [Related]
18. Meningitis due to Cryptococcus neoformans: treatment with posaconazole.
Flores VG; Tovar RM; Zaldivar PG; Martinez EA
Curr HIV Res; 2012 Oct; 10(7):620-3. PubMed ID: 22873639
[TBL] [Abstract][Full Text] [Related]
19. The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis.
Garvey EP; Sharp AD; Warn PA; Yates CM; Schotzinger RJ
J Antimicrob Chemother; 2018 Oct; 73(10):2815-2822. PubMed ID: 29947783
[TBL] [Abstract][Full Text] [Related]
20. Correlation of susceptibility of Cryptococcus neoformans to amphotericin B with clinical outcome.
Larsen RA; Bauer M; Pitisuttithum P; Sanchez A; Tansuphaswadikul S; Wuthiekanun V; Peacock SJ; Simpson AJ; Fothergill AW; Rinaldi MG; Bustamante B; Thomas AM; Altomstone R; Day NP; White NJ
Antimicrob Agents Chemother; 2011 Dec; 55(12):5624-30. PubMed ID: 21947402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
